Gene therapy for Parkinson’s disease: contemporary practice and emerging concepts

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590. .
   PubMed Web of Science ®Google Scholar
• Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4(1):21. .
   PubMedGoogle Scholar
• Espay AJ, Morgante F, Merola A, et al. Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol. 2018;84(6):797–811. .
   PubMed Web of Science ®Google Scholar
• Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(Supplement 1):S19–S32.
   PubMedGoogle Scholar
• Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease. Mov Disord. 2011;26(4):664–670.
   PubMed Web of Science ®Google Scholar
• Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014;22(4):692–701.
   PubMed Web of Science ®Google Scholar
• Han H, Yang J, Chen W, et al. A comprehensive review on histone-mediated transfection for gene therapy. Biotechnol Adv. 2019;37(1):132–144. .
   PubMed Web of Science ®Google Scholar
• Haggerty DL, Grecco GG, Reeves KC, et al. Adeno-associated viral vectors in neuroscience research. Mol Ther Methods Clin Dev. 2019;17:69–82.
   PubMed Web of Science ®Google Scholar
• Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;101(5):839–862.
   PubMed Web of Science ®Google Scholar
• Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum Gene Ther. 2015;26(5):257–265.
   PubMed Web of Science ®Google Scholar
• Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci. 2007;27(37):9928–9940.
   PubMed Web of Science ®Google Scholar
• Hanlon KS, Meltzer JC, Buzhdygan T, et al. Selection of an efficient AAV vector for robust CNS transgene expression. Mol Ther Methods Clin Dev. 2019;15:320–332.
   PubMed Web of Science ®Google Scholar
• Rosario AM, Cruz PE, Ceballos-Diaz C, et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev. 2016;3:16026.
   PubMed Web of Science ®Google Scholar
• Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28(4):308–313.
   PubMed Web of Science ®Google Scholar
• Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285–297.
   PubMed Web of Science ®Google Scholar
• Christine CW, Bankiewicz KS, Van Laar AD, et al., Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease. Ann Neurol. 2019;85(5): 704–714. .
   PubMed Web of Science ®Google Scholar
• Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263–267. .
   PubMed Web of Science ®Google Scholar
• Palfi S, Leventhal L, Chu Y, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002;22(12):4942–4954. .
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Blömer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol. 1998;72(10):8150–8157. .
   PubMed Web of Science ®Google Scholar
• Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873–9880. .
   PubMed Web of Science ®Google Scholar
• Tambasco N, Romoli M, Calabresi P. Levodopa in parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239–1252.
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Eberling JL, Kohutnicka M, et al., Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164(1): 2–14. .
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS, et al., Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20): 1662–1669. .
   PubMed Web of Science ®Google Scholar
• Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. Mol Ther. 2010;18(9):1731–1735. .
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–560.
   PubMed Web of Science ®Google Scholar
• Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383(9923):1138–1146.
   PubMed Web of Science ®Google Scholar
• Kells AP, Eberling J, Su X, et al., Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010;30(28): 9567–9577. .
   PubMed Web of Science ®Google Scholar
• Pascual A, Hidalgo-Figueroa M, Gómez-Díaz R, et al. GDNF and protection of adult central catecholaminergic neurons. J Mol Endocrinol. 2011;46(3):R83–R92.
   PubMed Web of Science ®Google Scholar
• Richardson RM, Kells AP, Rosenbluth KH, et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson’s disease. Mol Ther. 2011;19(6):1048–1057.
   PubMed Web of Science ®Google Scholar
• Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 1996;380(6571):252–255.
   PubMed Web of Science ®Google Scholar
• Tomac A, Lindqvist E, Lin LF, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373(6512):335–339. .
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589–595.
   PubMed Web of Science ®Google Scholar
• Heiss JD, Lungu C, Hammoud DA, et al., Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson’s disease. Mov Disord. 2019;34(7): 1073–1078. .
   PubMed Web of Science ®Google Scholar
• Whone A, Luz M, Boca M, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain. 2019;142(3):512–525. .
   PubMed Web of Science ®Google Scholar
• Whone AL, Boca M, Luz M, et al. Extended treatment with glial cell line-derived neurotrophic factor in Parkinson’s disease. J Parkinsons Dis. 2019;9(2):301–313. .
   PubMedGoogle Scholar
• Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384(6608):467–470.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L, et al., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5): 400–408. .
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Bartus RT, Siffert J, et al., Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12): 1164–1172. .
   PubMed Web of Science ®Google Scholar
• Olanow C, Bartus RT, Baumann TL, et al., Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2): 248–257. .
   PubMed Web of Science ®Google Scholar
• Gatto EM, Da Prat G, Etcheverry JL, et al. Parkinsonisms and glucocerebrosidase deficiency: a comprehensive review for molecular and cellular mechanism of glucocerebrosidase deficiency. Brain Sci. 2019;9(2):30.
   Web of Science ®Google Scholar
• Rocha EM, Smith GA, Park E, et al. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495–503.
   PubMed Web of Science ®Google Scholar
• Morabito G, Giannelli SG, Ordazzo G, et al. AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol Ther. 2017;25(12):2727–2742. .
   PubMed Web of Science ®Google Scholar
• Erlander MG, Tillakaratne NJ, Feldblum S, et al. Two genes encode distinct glutamate decarboxylases. Neuron. 1991;7(1):91–100. .
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, et al., AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4): 309–319. .
   PubMed Web of Science ®Google Scholar
• Niethammer M, Tang CC, LeWitt PA, et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease. JCI Insight. 2017;2(7):e90133. .
   PubMed Web of Science ®Google Scholar
• Niethammer M, Tang CC, Vo A, et al. Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity. Sci Transl Med. 2018;10(469):eaau0713. .
   PubMed Web of Science ®Google Scholar
• Hinderer C, Bell P, Katz N, et al. Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther. 2018;29(1):15–24. .
   PubMed Web of Science ®Google Scholar
• Salvatore MF, Ai Y, Fischer B, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol. 2006;202(2):497–505. .
   PubMed Web of Science ®Google Scholar
• Aly AE, Harmon BT, Padegimas L, et al. Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-hydroxydopamine model of parkinson’s disease. Mol Neurobiol. 2019;56(1):688–701. .
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Mirek H, Bringas J, et al. Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum Gene Ther. 2004;15(5):469–479. .
   PubMed Web of Science ®Google Scholar
• Bravo-Hernandez M, Tadokoro T, Navarro MR, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26(1):118–130.
   PubMed Web of Science ®Google Scholar
• Yager LM, Garcia AF, Wunsch AM, et al. The ins and outs of the striatum: role in drug addiction. Neuroscience. 2015;301:529–541.
   PubMed Web of Science ®Google Scholar
• Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980–1983. .
   PubMed Web of Science ®Google Scholar
• Fiandaca MS, Varenika V, Eberling J, et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage. 2009;47(Suppl 2):T27–T35. .
   PubMedGoogle Scholar
• Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther. 2006;17(3):291–302. .
   PubMed Web of Science ®Google Scholar
• Richardson RM, Kells AP, Martin AJ, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg. 2011;89(3):141–151. .
   PubMed Web of Science ®Google Scholar
• Chittiboina P, Heiss JD, Lonser RR. Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae. J Neurosurg. 2015;122(5):1173–1179.
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076–2080. .
   PubMed Web of Science ®Google Scholar
• Morrison PF, Laske DW, Bobo H, et al. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994;266(1 Pt 2):R292–R305. .
   PubMed Web of Science ®Google Scholar
• Hamilton JF, Morrison PF, Chen MY, et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol. 2001;168(1):155–161.
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Sudhakar V, Samaranch L, et al. AAV viral vector delivery to the brain by shape-conforming MR-guided infusions. J Control Release. 2016;240:434–442.
   PubMed Web of Science ®Google Scholar
• Sudhakar V, Naidoo J, Samaranch L, et al. Infuse-as-you-go convective delivery to enhance coverage of elongated brain targets: technical note. J Neurosurg. 2019:1–8. 10.3171/2019.4.JNS19826
   PubMed Web of Science ®Google Scholar
• Ciesielska A, Mittermeyer G, Hadaczek P, et al. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther. 2011;19(5):922–927. .
   PubMed Web of Science ®Google Scholar
• San Sebastian W, Samaranch L, Heller G, et al. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther. 2013;20(12):1178–1183. .
   PubMed Web of Science ®Google Scholar
• Zingg B, Chou XL, Zhang ZG, et al. AAV-mediated anterograde transsynaptic tagging: mapping corticocollicular input-defined neural pathways for defense behaviors. Neuron. 2017;93(1):33–47. .
   PubMed Web of Science ®Google Scholar
• Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for Parkinson’s disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis. 2012;48(2):228–235.
   PubMed Web of Science ®Google Scholar
• Parashos SA, Luo S, Biglan KM, et al. Measuring disease progression in early Parkinson disease: the National institutes of health exploratory trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014;71(6):710–716. .
   PubMed Web of Science ®Google Scholar
• Merola A, Sturchio A, Hacker S, et al. Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. Expert Rev Neurother. 2018;18(11):825–845. .
   PubMed Web of Science ®Google Scholar
• Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain. 2009;132(11):2970–2979. .
   PubMedGoogle Scholar
• Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33(2):200–209. .
   PubMed Web of Science ®Google Scholar
• Ribeiro MJ, Vidailhet M, Loc’h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59(4):580–586. .
   PubMedGoogle Scholar
• Benamer HT, Patterson J, Wyper DJ, et al. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692–698. .
   PubMed Web of Science ®Google Scholar
• Pavese N, Rivero-Bosch M, Lewis SJ, et al. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56(3):1463–1468. .
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37(7):1129–1133.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol. 2005;32(2):123–128. .
   PubMed Web of Science ®Google Scholar
• Pirker W, Holler I, Gerschlager W, et al. Measuring the rate of progression of Parkinson’s disease over a 5-year period with beta-CIT SPECT. Mov Disord. 2003;18(11):1266–1272. .
   PubMed Web of Science ®Google Scholar
• Brück A, Aalto S, Rauhala E, et al. A follow-up study on 6-[18 F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord. 2009;24(7):1009–1015. .
   PubMed Web of Science ®Google Scholar
• Morrish PK, Sawle GV, Brooks DJ. An [18 F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease. Brain. 1996;119(2):585–591.
   PubMedGoogle Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101. .
   PubMed Web of Science ®Google Scholar
• Chalon S, Vercouillie J, Payoux P, et al. The story of the dopamine transporter PET Tracer LBT-999: from conception to clinical use. Front Med (Lausanne). 2019;6:90.
   PubMed Web of Science ®Google Scholar
• Fu JF, Klyuzhin I, McKenzie J, et al. Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson’s disease induced presynaptic alterations. Neuroimage Clin. 2019;23:101856.
   PubMed Web of Science ®Google Scholar
• Kramer V, Juri C, Riss PJ, et al. Pharmacokinetic evaluation of [(18)F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain. Eur J Nucl Med Mol Imaging. 2019. Epub ahead of print. 10.1007/s00259-019-04594-z.
   Web of Science ®Google Scholar
• Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med. 2010;2(21):21ra16. .
   PubMed Web of Science ®Google Scholar
• Forrester JV, McMenamin PG, Dando SJ. CNS infection and immune privilege. Nat Rev Neurosci. 2018;19(11):655–671.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol. 2017;4(1):511–534.
   PubMed Web of Science ®Google Scholar
• Meliani A, Boisgerault F, Hardet R, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018;9(1):4098. .
   PubMedGoogle Scholar
• Schnepp BC, Jensen RL, Chen CL, et al. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005;79(23):14793–14803. .
   PubMed Web of Science ®Google Scholar
• Nakai H, Montini E, Fuess S, et al. Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol Ther. 2003;7(1):101–111. .
   PubMed Web of Science ®Google Scholar
• Castle MJ, Turunen HT, Vandenberghe LH, et al. Controlling AAV tropism in the nervous system with natural and engineered capsids. Methods Mol Biol. 2016;1382:133–149.
   PubMedGoogle Scholar
• Kanaan NM, Sellnow RC, Boye SL, et al. Rationally Engineered AAV capsids improve transduction and volumetric spread in the CNS. Mol Ther Nucleic Acids. 2017;8:184–197.
   PubMedGoogle Scholar
• Tordo J, O’Leary C, Antunes ASLM, et al. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain. 2018;141(7):2014–2031. .
   PubMedGoogle Scholar
• Naidoo J, Stanek LM, Ohno K, et al. Extensive transduction and enhanced spread of a modified AAV2 capsid in the non-human primate CNS. Mol Ther. 2018;26(10):2418–2430.
   PubMed Web of Science ®Google Scholar
• Tervo DG, Hwang BY, Viswanathan S, et al. A designer AAV variant permits efficient retrograde access to projection neurons. Neuron. 2016;92(2):372–382.
   PubMed Web of Science ®Google Scholar
• Jackson KL, Dayton RD, Deverman BE, et al. Corrigendum: better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front Mol Neurosci. 2016;9:154.
   PubMed Web of Science ®Google Scholar
• McLean JR, Smith GA, Rocha EM, et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014;576:73–78.
   PubMed Web of Science ®Google Scholar
• Watakabe A, Ohtsuka M, Kinoshita M, et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res. 2015;93:144–157.
   PubMed Web of Science ®Google Scholar
• Dashkoff J, Lerner EP, Truong N, et al. Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9. Mol Ther Methods Clin Dev. 2016;3:16081.
   PubMed Web of Science ®Google Scholar
• Georgiou E, Sidiropoulou K, Richter J, et al. Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model. Brain. 2017;140(3):599–616. .
   PubMedGoogle Scholar
• Kennedy LH, Rinholm JE. Visualization and live imaging of oligodendrocyte organelles in organotypic brain slices using adeno-associated virus and confocal microscopy. J Vis Exp. 2017;128:56237.
   Google Scholar
• Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci Transl Med. 2018;10(451):eaar5429.
   PubMed Web of Science ®Google Scholar